Seprase-Targeting CTC Capture for Invasive Phenotype Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for capturing circulating tumor cells (CTCs) are inadequate, particularly for invasive sub-populations with low or no EpCAM expression, leading to poor sensitivity and specificity in detecting metastatic cancer, as they fail to target rare and elusive CTC sub-populations.
Innovation Solution
A method utilizing a mammalian seprase-targeting affinity reagent, such as antibodies, nucleic acid aptamers, or peptide ligands, to capture CTCs, which are then detected using biomarkers like EpCAM, CD146, and others, enabling the isolation and analysis of invasive CTCs through a microfluidic device.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EpCAM-targeting antibodies are used to capture CTCs, then epithelial CTCs can be detected, but invasive CTCs with low or no EpCAM expression are missed
Solution Approach 1:
The patent employs a dual-targeting strategy using both EpCAM antibodies and seprase-targeting affinity reagents to capture different CTC sub-populations. This multi-functional approach allows the system to detect both epithelial CTCs (via EpCAM) and invasive CTCs (via seprase), thereby resolving the contradiction between reliable detection of epithelial cells and the ability to detect diverse CTC sub-populations including invasive ones with low or no EpCAM expression.
Solution Approach 2:
The invention uses composite capture reagents that combine EpCAM-targeting antibodies with seprase-targeting affinity reagents. This composite approach creates a more versatile capture system that can simultaneously bind to both EpCAM-positive and seprase-positive CTCs, effectively addressing the limitation of using单一 EpCAM-targeting methods and improving overall detection reliability across diverse CTC phenotypes.
2Productivity
If positive selection using EpCAM antibodies is used, then CTC enrichment is achieved, but sensitivity and specificity remain poor for metastatic cases
Solution Approach 1:
The patent introduces seprase-targeting affinity reagents as an intermediary capture mechanism to complement EpCAM antibodies. Since seprase is overexpressed on invasive CTCs and has different expression patterns compared to EpCAM, this intermediary approach allows for the detection of CTCs that may be missed by EpCAM alone, thereby improving both sensitivity and specificity while maintaining enrichment efficiency.
Solution Approach 2:
The invention changes the detection parameters by targeting a different molecular marker (seprase) with distinct expression characteristics compared to EpCAM. This parameter change enables the detection of invasive CTCs that have down-regulated EpCAM, thus improving measurement precision for metastatic cases while preserving the productivity of CTC enrichment through the combined approach.
3Ease of operation
If single-marker targeting is used, then assay simplicity is maintained, but detection of invasive CTCs is ineffective
Solution Approach 1:
The patent segments the CTC detection process into two distinct targeting components: EpCAM antibody binding and seprase affinity reagent binding. This segmentation allows each component to be optimized for its specific target while maintaining overall assay simplicity. The modular nature of the dual-targeting approach enables effective detection of invasive CTCs without significantly complicating the assay procedure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively captures and analyzes CTCs, including those with invasive phenotypes that have down-regulated EpCAM, improving the detection of metastatic potential and prognosis by assessing the ratio of seprase-expressing to EpCAM-expressing cells.
Implementation Method 1
contacting the sample with a mammalian seprase-targeting affinity reagent
Implementation Method 2
isolation and analysis of invasive CTCs through a microfluidic device
Data Source
AI summary
This invention provides methods and compositions for capturing circulating tumor cells (CTCs) as well as various divergent CTC phenotypes using seprase-specific affinity reagents. Methods of analyzing CTCs and assessing their metastatic potential in vivo and in vitro are also disclosed.